Pancreatic Cancer Research

ResearcherBirmingham VA Medical CenterActive in the last 2 years

Robert C.A.M. van Waardenburg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0716-1670; OpenAlex author ID A5079685102. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
3
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 4

  1. DNA repair status as a guide for pancreatic ductal adenocarcinoma treatment, an old view for a new future. Co-author DOI 10.1016/j.canlet.2024.217222↗
  2. The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells. Co-author DOI 10.3389/fonc.2022.925718↗
  3. The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.3390/cancers13143470↗
  4. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. Co-author DOI 10.1016/j.ebiom.2019.05.035↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aubrey Lynn Miller · 3 shared papers, 2019–2022 · strength 0.42
  2. Patrick L. Garcia · 3 shared papers, 2019–2022 · strength 0.42
  3. Karina Jin Yoon · 3 shared papers, 2019–2022 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.